as of 12-11-2025 3:44pm EST
Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease are seeking to treat, a linker, and an antigen-binding fragment, that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.
| Founded: | 1984 | Country: | United States |
| Employees: | N/A | City: | WALTHAM |
| Market Cap: | 1.9B | IPO Year: | 2020 |
| Target Price: | $40.25 | AVG Volume (30 days): | 3.2M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 16 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.62 | EPS Growth: | N/A |
| 52 Week Low/High: | $6.36 - $28.96 | Next Earning Date: | 11-05-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Machine learning model trained on 25+ technical indicators
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Chief Medical Officer
Avg Cost/Share
$20.72
Shares
880
Total Value
$18,233.60
Owned After
87,510
SEC Form 4
Chief Commercial Officer
Avg Cost/Share
$20.72
Shares
144
Total Value
$2,983.68
Owned After
94,729
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Kerr Douglas | DYN | Chief Medical Officer | Dec 5, 2025 | Sell | $20.72 | 880 | $18,233.60 | 87,510 | |
| Cox John | DYN | CEO & President | Dec 5, 2025 | Sell | $20.72 | 2,662 | $55,156.64 | 196,877 | |
| Friedl-Naderer Johanna | DYN | Chief Commercial Officer | Dec 5, 2025 | Sell | $20.72 | 144 | $2,983.68 | 94,729 |
See how DYN stacks up against similar companies in the market
Enhance your trading experience with our free tools
The information presented on this page, "DYN Dyne Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.